PMID: 9432985Feb 7, 1998Paper

Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes

The Journal of Experimental Medicine
E JägerA Knuth

Abstract

A growing number of human tumor antigens have been described that can be recognized by cytotoxic T lymphocytes (CTLs) in a major histocompatibility complex (MHC) class I-restricted fashion. Serological screening of cDNA expression libraries, SEREX, has recently been shown to provide another route for defining immunogenic human tumor antigens. The detection of antibody responses against known CTL-defined tumor antigens, e.g., MAGE-1 and tyrosinase, raised the question whether antibody and CTL responses against a defined tumor antigen can occur simultaneously in a single patient. In this paper, we report on a melanoma patient with a high-titer antibody response against the "cancer-testis" antigen NY-ESO-1. Concurrently, a strong MHC class I-restricted CTL reactivity against the autologous NY-ESO-1-positive tumor cell line was found. A stable CTL line (NW38-IVS-1) was established from this patient that reacted with autologous melanoma cells and with allogeneic human histocompatibility leukocyte antigen (HLA)-A2(-), NY-ESO-1-positive, but not NY-ESO-1-negative, melanoma cells. Screening of NY-ESO-1 transfectants with NW38-IVS-1 revealed NY-ESO-1 as the relevant CTL target presented by HLA-A2. Computer calculation identified 26 pept...Continue Reading

References

Sep 1, 1979·Proceedings of the National Academy of Sciences of the United States of America·H TowbinJ Gordon
Jun 1, 1992·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·K OrnvoldE Ralfkiaer
Jan 1, 1992·Immunogenetics·K Satyanarayana, J L Strominger
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·A KnuthK H Meyer zum Büschenfelde
Mar 15, 1987·International Journal of Cancer. Journal International Du Cancer·M HérinT Boon
Jul 1, 1983·The Journal of Experimental Medicine·B Mukherji, T J MacAlister
Jun 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·A KnuthL J Old
Dec 1, 1981·Journal of Epidemiology and Community Health·P Cook-MozaffariR Doll
Aug 15, 1995·Proceedings of the National Academy of Sciences of the United States of America·P G CoulieT Boon
Mar 1, 1994·The Journal of Experimental Medicine·A B BakkerC G Figdor
Dec 5, 1995·Proceedings of the National Academy of Sciences of the United States of America·U SahinM Pfreundschuh
Mar 1, 1996·The Journal of Experimental Medicine·T Boon, P van der Bruggen
Jul 3, 1996·International Journal of Cancer. Journal International Du Cancer·E JägerA Knuth
Dec 11, 1995·International Journal of Cancer. Journal International Du Cancer·M MarchandY Humblet
Oct 1, 1996·Current Opinion in Immunology·M L Disis, M A Cheever
Mar 4, 1997·Proceedings of the National Academy of Sciences of the United States of America·Y T ChenL J Old
Apr 10, 1997·International Journal of Cancer. Journal International Du Cancer·E JägerA Knuth

❮ Previous
Next ❯

Citations

Oct 3, 1999·International Journal of Cancer. Journal International Du Cancer·M J ScanlanL J Old
Mar 20, 2002·Cancer·Mirjana Urosevic, Reinhard Dummer
May 15, 2001·International Journal of Cancer. Journal International Du Cancer·A A JungbluthL J Old
Mar 10, 2001·Biochemical and Biophysical Research Communications·T NakatsuraY Nishimura
Aug 24, 1999·Medical Oncology·P JantscheffC Rochlitz
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·Y ObataS Miura
Mar 11, 2005·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Ken-ichi Hanada, James C Yang
Aug 17, 2004·Cancer Immunology, Immunotherapy : CII·Luisa NovellinoGiorgio Parmiani
Jan 1, 2005·Cancer Immunology, Immunotherapy : CII·Tobias KrügerStefan Stevanović
Sep 28, 2005·Cancer Immunology, Immunotherapy : CII·Zhaojun SunPierre van der Bruggen
Mar 15, 2006·Cancer Immunology, Immunotherapy : CII·Jun-Feng HanYu-Zhang Wu
Sep 9, 2006·Cancer Immunology, Immunotherapy : CII·Pedro M S AlvesFrédéric Lévy
Nov 11, 2006·Cancer Immunology, Immunotherapy : CII·Danièle GodelaineAline Van Pel
Jul 2, 2008·Cancer Immunology, Immunotherapy : CII·Peng-Yu ZhangWen-Bin Li
Nov 11, 2008·Cancer Immunology, Immunotherapy : CII·Manuela IeroLicia Rivoltini
Jun 2, 2010·Cancer Immunology, Immunotherapy : CII·A HellerN A Giese
Oct 29, 2011·Cancer Immunology, Immunotherapy : CII·Jun ZhouF Stephen Hodi
Jun 23, 2012·Cancer Immunology, Immunotherapy : CII·Thomas F GajewskiSeng-Ryong Woo
May 1, 2004·Cancer Chemotherapy and Pharmacology·Argun AkcakanatKatsuyoshi Hatakeyama
Nov 11, 2006·Springer Seminars in Immunopathology·Lydie CassardCatherine Sautès-Fridman
Jul 15, 2009·International Journal of Colorectal Disease·Yujun HeYuzhang Wu
Sep 28, 2007·Journal of Cancer Research and Clinical Oncology·Yi ShaoHai-Tao Zhao
Jun 30, 2005·Cancer Metastasis Reviews·Yutaka KawakamiYuriko Matsuzaki
Dec 21, 2000·Current Oncology Reports·L W ThompsonC L Slingluff
Jul 21, 2004·Clinics in Dermatology·Ian KomenakaHoward L Kaufman
Aug 23, 2002·Journal of Immunological Methods·Barbara-ann GuinnGhulam J Mufti
Apr 12, 2003·Leukemia Research·Philipp NiemeyerUgur Sahin
Sep 27, 2003·Journal of Neuroimmunology·Anne PlonquetPierre Langlade-Demoyen
Jan 9, 2001·Experimental Hematology·J GreinerM Schmitt
Mar 3, 2001·Current Opinion in Immunology·A N HoughtonN E Blachere
Oct 31, 1998·Current Opinion in Immunology·D M Pardoll, S L Topalian
Jul 6, 2002·Critical Reviews in Oncology/hematology·Rong-Fu WangHan Ying
Apr 29, 2005·The Journal of Molecular Diagnostics : JMD·Norifumi NakaKazuyuki Itoh

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.